Ribose-cysteine protects against the development of atherosclerosis in apoE-deficient mice.

Ribose-cysteine is a synthetic compound designed to increase glutathione (GSH) synthesis. Low levels of GSH and the GSH-dependent enzyme, glutathione peroxidase (GPx), is associated with cardiovascular disease (CVD) in both mice and humans. Here we investigate the effect of ribose-cysteine on GSH, GPx, oxidised lipids and atherosclerosis development in apolipoprotein E-deficient (apoE-/-) mice. Female 12-week old apoE-/- mice (n = 15) were treated with 4-5 mg/day ribose-cysteine in drinking water for 8 weeks or left untreated. Blood and livers were assessed for GSH, GPx activity and 8-isoprostanes. Plasma alanine transferase (ALT) and lipid levels were measured. Aortae were quantified for atherosclerotic lesion area in the aortic sinus and brachiocephalic arch and 8-isoprostanes measured. Ribose-cysteine treatment significantly reduced ALT levels (p<0.0005) in the apoE-/- mice. Treatment promoted a significant increase in GSH concentrations in the liver (p<0.05) and significantly increased GPx activity in the liver and erythrocytes of apoE-/-mice (p<0.005). The level of 8-isoprostanes were significantly reduced in the livers and arteries of apoE-/- mice (p<0.05 and p<0.0005, respectively). Ribose-cysteine treatment showed a significant decrease in total and low density lipoprotein (LDL) cholesterol (p<0.05) with no effect on other plasma lipids with the LDL reduction likely through upregulation of scavenger receptor-B1 (SR-B1). Ribose-cysteine treatment significantly reduced atherosclerotic lesion area by >50% in both the aortic sinus and brachiocephalic branch (p<0.05). Ribose-cysteine promotes a significant GSH-based antioxidant effect in multiple tissues as well as an LDL-lowering response. These effects are accompanied by a marked reduction in atherosclerosis suggesting that ribose-cysteine might increase protection against CVD.

Introduction

Atherosclerosis is the disease process occurring in arteries underpinning the development of cardiovascular disease [1]. Elevated levels of LDL, Lp(a) and remnant lipoproteins have all been established as major risk factors for the development of atherosclerosis in humans [2-4]. Furthermore, the amount of oxidised phospholipids (OxPL) present on these atherogenic lipoproteins associates with vascular disease [5, 6]. Oxidised phospholipids within lipoproteins trapped in the artery promote the activation and infiltration of monocytes that subsequently differentiate into pro-inflammatory macrophages which enable foam cell formation and atherosclerosis development (1).

Oxidised phospholipids are catabolised by glutathione peroxidase (GPx; E.C. 1.11.1.9), an enzyme that catalyses their reduction to lipid alcohols [7]. A low activity of erythrocyte GPx1, the ubiquitous intracellular form of GPx, has been associated with cardiovascular disease in multiple clinical studies [8-10]. Furthermore, a recent meta-analysis of the rs1050450 polymorphism in GPx1 which reduces its activity, is associated with increased CVD risk [11]. An age-related decline in the activity of GPx3, the extracellular form in plasma, has also recently been reported to be associated with cardiovascular disease [12]. The activity of GPx depends on the availability of its cofactor glutathione (GSH), an endogenous tripeptide made from cysteine, glutamine and glycine that provides the reducing equivalents for many redox reactions protecting the body from oxidative stress [13]. Low plasma levels of GSH have been reported in cardiovascular disease patients [14] and in animal models of atherosclerosis [15].

Cysteine-delivery agents such as N-acetylcysteine (NAC) and D-ribose-L-cysteine (ribose-cysteine) can promote the synthesis of GSH [16, 17]. While NAC increases GSH levels at single high doses in humans (around 1.0 g/kg body weight), toxic side effects have been reported [18]. In comparison, ribose-cysteine generates a slower more sustained release of L-cysteine than NAC increasing GSH levels in multiple tissues without any toxicity when administered in a single high dose to mice (2.0 g/kg body weight) [19]. A recent study showed that ribose-cysteine given daily for 8 weeks at a dose of 0.16g/kg/day significantly increased both the liver and plasma GSH levels in a mouse model of hyperlipidaemia without toxicity [20]. Furthermore, this was associated with a significantly increased activity of GPx in the liver and blood and a reduction in the level of oxidised lipids in arteries [20].

The apoE-deficient (apoE -/-) mouse is the most widely used mouse model for atherosclerosis studies with the defective remnant lipoprotein clearance in these animals promoting the spontaneous development of atherosclerotic lesions within 20 weeks [21]. Multiple studies have shown that oxidative stress is a fundamental mechanism underlying the development of atherosclerosis in this model. Plasma and aortic isoprostanes are elevated in these animals [22] and proteomic studies of aortic tissue show the animals lose their ability to mount an antioxidant response with the onset of atherosclerosis [23]. Furthermore, Biwas et al [15] showed a reduction in GSH synthesis and GPx1 activity in the aortae of apoE-/- mice before the onset of oxidative stress and atherosclerosis development. The importance of Gpx1 in protecting against atherosclerosis has been established in this model with a knockout of GPx1 accelerating atherosclerosis progression [24].

Here we investigated the effect of ribose-cysteine supplementation on GSH-based antioxidant activity and atherosclerosis development in the apoE-/- mouse. We hypothesised that ribose-cysteine would increase the supply of L-cysteine to the liver, blood and arteries resulting in the promotion of GSH synthesis and increased GPx activity (Fig 1) which may, in turn, reduce atherosclerosis development through a reduction in OxPL content in the arteries.

Fig 1

Proposed mode of action of ribose-cysteine.

Ribose-cysteine releases L-cysteine via hydrolysis in the plasma compartment which is taken up by the liver and utilised to promote GSH synthesis. The increase in GSH promotes an increase in GPx activity to give a reduction in oxidised lipid content. Excess GSH is exported by the liver.

Materials and methods

Mice

Female apoE-/- mice on a C57BL/6 background were obtained from the Animal Resource Centre (Murdoch, WA). Ethical approval for this study was granted by the Otago University Animal Ethics Committee. Mice were fed a normal chow-diet (Ruakura 86 Sharpes, Carterton, New Zealand) and housed in a specific pathogen free (SPF) facility on a 12 hour light/dark cycle at 22°C with free access to water and food. Daily water intake and weekly body weights were recorded. Fifteen 12-week old female apoE-/- mice were treated with 1 mg/mL ribose-cysteine in the drinking water (made fresh every 2–3 days) for 8 weeks receiving an average dose of 4–5 mg/day/mouse (0.16–0.21 g/kg body weight) based on water intake. The stability of ribose-cysteine in water was analysed by HILAC-MS analysis as described in section 2.3. Fifteen 12-week old apoE-/- without ribose-cysteine in their drinking water were used as untreated controls. Ribose-cysteine was prepared by Chemica Inc. (Los Angeles, CA) and provided by Max International, LLC (Salt Lake City, UT).

Blood and tissue collection

After supplementation, mice were sacrificed by CO2 inhalation and whole blood collected via cardiac puncture into EDTA and plasma and erythrocytes were isolated. Samples were either used fresh or stored at -80°C with 0.05% butylhydroxytoluene (BHT) until use. Tissues were perfused with heparin 40 U/ml in phosphate buffered saline (PBS) through the left ventricle. Livers from all animals and the aortae from five animals were harvested and either used fresh or frozen in liquid nitrogen and stored at -80°C with 0.05% BHT until use. The aortae in ten animals of each group were further perfused with 4% (w/v) paraformaldehyde (pH 7.5), carefully dissected out and further fixed in 4% (w/v) paraformaldehyde overnight. The aortae were then washed in PBS and stored in 70% (v/v) ethanol for histological assessment. The aortae from the remaining 5 animals in each group were harvested without fixation and stored at -80°C with 0.05% BHT until use.

HILIC-LCMS analysis of ribose-cysteine and related metabolites in plasma

Polar metabolites were extracted from 20 μL of mouse plasma with 180 μL of acetonitrile: methanol (2:2, v/v) containing 5 μM of stable-isotope-labeled (13C) internal standards. LCMS analysis of the extracted metabolites was performed as previously described [25]. Briefly, metabolites (7 μL) were separated on a SeQuant ZIC–pHILIC column (5μm, 150 × 4.6 mm, Merck Millipore) using the Agilent 1200 LC system (Agilent Technologies, Santa Clara, CA) coupled to an Agilent 6545 QTOF mass spectrometer. Ribose-cysteine and its metabolites (D-ribose/any 5-carbon sugar and L-cysteine, see Fig 1) were targeted for analysis. Peak area integration and targeted data matrix was generated on the retention time and molecular masses matching to the authentic standards for each metabolite using MassHunter TOF Quantitative Analysis Software (Agilent Technologies). The stability of ribose-cysteine (20 μM) in water and in plasma ex vivo up to 48 hours was tested following the same targeted pHILIC-LC-MS analysis.

Plasma ALT measurements

Levels of alanine transferase (ALT) were measured in mouse plasma as a marker of hepatotoxicity using the Infinity TM ALT (GPT) Liquid Stable Reagent (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's instructions.

GSH measurement

Fresh liver tissue (10–20 mg) was homogenised in 400 μL PBS and following centrifugation, the supernatant was diluted 1:60 with de-ionized water. Fresh plasma was diluted 1:10 with de-ionized water. One hundred μl of diluted homogenate or plasma was mixed with 100 μl of 20 mM NEM to protect thiol groups from oxidation. An isotopically-labelled internal standard of GSH-NEM was added to the alkylated samples, the protein was precipitated by adding ice-cold ethanol (80% v/v) and the protein pellet removed by centrifugation at 12000 g for 5 min. GSH-NEM was measured in the supernatant by stable isotope dilution liquid chromatography tandem mass spectrometry assay (LC-MS/MS) as described before [26]. The GSH content of tissue and plasma was normalized to the amount of homogenized tissue and the protein concentration measured in plasma based on the method by Bradford [27].

GPx activity

The GPx activity in liver, erythrocytes and plasma was measured using a commercial kit (RS504, Randox Laboratories, Crumlin, UK) with samples prepared according to Kader et al. [20]. Plasma was diluted in PBS (1 in 20) before GPx activity measurement.

Oxidised lipid analysis

Total 8-isoprostanes (free and esterified) were measured in the livers and in the aortic arches pooled from five animals using the EIA kit (Cayman Chemical, Ann Arbor, MI) with samples prepared according to the manufacturer’s protocol. Free 8-isoprostanes were measured in plasma using the same kit.

Lipid analysis

Plasma total cholesterol and triglycerides concentrations were measured using enzymatic reagents from Roche Diagnostics (Mannheim, Germany). High density lipoprotein (HDL) cholesterol concentrations were measured according to Purcell-Huynh et al. [28]. The LDL cholesterol concentrations were calculated using the Friedewald equation [29].

Western blot analysis of LDLR

Liver homogenates (40 μg) were separated by SDS PAGE on 7.5% polyacrylamide gels under reducing conditions and subject to western blot analysis using an anti-low density lipoprotein receptor (LDLR) antibody (Abcam, Cambridge, ab30532), an anti-HMGCoA reductase antibody (Abcam, ab174830), an anti-SR-B1 antibody (Novus Biologicals, Littleton, CO, NB400-113) and an anti-actin antibody (Sigma, St Louis, MI). Blots were washed and then incubated with a goat anti-rabbit IgG-hrp antibody (Thermo Scientific, Waltham, MA). Membranes were developed using enhanced chemiluminescence (ECL) on the LI-COR Odyssey (LI-COR Biosciences Inc, Lincoln, NE). Protein quantification was performed by Image Studio Lite (LI-COR Biosciences, Inc) with protein normalised against actin.

Histological assessment of aortae

The aortic arch from the aortic ring to the first intercostal branch was separated from the rest of the paraformaldehyde-fixed aorta. The aortic sinus, from the aortic ring to midway along the ascending aorta, was paraffin embedded for transverse sectioning and the remaining aortic arch embedded separately for longitudinal sectioning. Sequential serial transverse 4-μm sections were made from both the aortic sinus and aortic arch. For the aortic sinus, the transverse section that included at least two of the three leaflet commissures (point of wall attachment) was used for quantification to ensure a similar anatomical site was used for all animals. For the brachiocephalic branch, the longitudinal section with the maximal vessel diameter in each animal was used to avoiding oblique section artefacts and to ensure that a similar anatomical location was used for comparison. Sections were stained with Verhoeff's elastic stain and Curtis' modified van Gieson stain and plaque area quantified, by a blinded assessor, to avoid selection bias as previously described [30].

Statistical analysis

All statistical analysis except the metabolomics analysis was performed using GraphPad Prism v7 (GraphPad, San Diego, CA). Statistical analysis for the effect of ribose-cysteine on GSH, GPx, oxidised lipids, plasma lipids and lesion area were assessed using an unpaired student t-test. All values are expressed as means ± SEM unless specified. A difference with p< 0.05 was considered as significant. The metabolomics MS data were processed with Agilent Mass Hunter Software. The data was pre-treated before statistical analysis to account for biological, experimental and instrument variations by performing a natural log transformation and each metabolite was median normalised to the median of each sample. The resulting data (groups) were analysed using a student t-test for unpaired data with p< 0.05. Results of the t-test were controlled for false positives using the Benjamini-Hochberg method. The above statistical test and the generation of box plots of metabolites were performed using the in-house Metabolomics R package.

Results

Ribose-cysteine is rapidly metabolised

Ribose-cysteine was shown to be stable up to 48 hours in water and plasma ex vivo (S1 Fig). Ribose-cysteine was undetectable in the plasma of treated and control animals suggesting a rapid metabolism in treated animals. The expected metabolites of ribose-cysteine, L-cysteine and D-ribose, were detectable in the plasma with L-cysteine levels unchanged between treated and untreated control mice. While D-Ribose levels appeared to be decreased in treated mice (p = 0.03, S2 Fig), this result should be treated with caution since the metabolomic analysis could not distinguish D-ribose from other 5 carbon sugars.

No evidence of liver toxicity

There was no significant difference between the body or liver weights of ribose-cysteine treated versus untreated control mice (Table 1). Plasma ALT measurements showed the ribose-cysteine treated mice to have significantly lower ALT activity compared to controls (6.46 ± 1.40 vs 13.04 ± 0.88 U/mL, p< 0.0005, Table 1).

Table 1

Body weight, liver weight and ALT measurements after 8 weeks of ribose-cysteine treatment.

	Control	Ribose-cysteine	p value
Body weight (g)	22.87 ± 0.31	22.80 ± 0.33	0.8828
Liver weight (g)	1.16 ± 0.05	1.07 ± 0.05	0.2457
ALT (U/mL)	13.04 ± 0.88	6.46 ± 1.40	0.0005

Ribose-cysteine increases GSH levels in the liver

Liver GSH was significantly increased in ribose-cysteine treated mice compared to controls (6.85 ± 0.43 vs 5.48 ± 0.47 μmol/g of tissue, p< 0.05, Fig 2A). There was no significant difference in plasma GSH between treated mice and control mice (p = 0.44, Fig 2B).

Fig 2

Ribose-cysteine increases liver GSH and GPx activity and decreases total 8-isoprostanes in liver and aortae of apoE-/- mice.

ApoE-/- (12-week old) were treated with 4–5 mg/day ribose-cysteine in their drinking water for 8 weeks with control apoE-/- mice given normal drinking water (n = 15 per group). The GSH content of tissues and plasma was measured by LC-MS. The GPx activity in liver, erythrocytes and plasma was measured by spectrophotometric assay. Total 8-isoprostanes in liver, aortae and plasma were measured by an 8-isoprostane EIA kit. (A) Liver GSH (n = 15), (B) Plasma GSH (n = 15), (C) Liver GPx activity (n = 15), (D) Erythrocyte GPx activity (n = 15), (E) Plasma GPx activity (n = 15), (F) Total 8-isoprostane in the liver (n = 15), (G) Free 8-isoprostanes in the plasma (n = 15), (H) Total 8-isoprostane in a sample of 5 pooled arteries analysed in triplicate. *p < 0.05, *** p < 0.001, **** p < 0.0001, ns; not significant. Error bars indicate means ± SEM.

Ribose-cysteine increases GPx activity in the liver and erythrocytes

The GPx activity in liver tissue was significantly higher in ribose-cysteine treated mice compared to controls (0.98 ± 0.04 vs 0.44 ±0.05 U/mg protein, p< 0.0001, Fig 2C). Erythrocyte GPx activity was also significantly higher in the treated mice (8.60 ± 1.13 vs 3.97 ± 0.56 U/mg protein, p< 0.001 respectively, Fig 2D). Plasma GPx activity was not altered in ribose-cysteine treated mice (p = 0.22, Fig 2E).

Ribose-cysteine reduces oxidised lipid levels in the liver and arteries

Analysis of total 8-isoprostanes as a marker of oxidised lipids in the liver showed a significant reduction with ribose-cysteine treatment (118.4 ± 9.7 vs 177.8 ± 26.0 pg/mg protein in controls, p< 0.05, Fig 2F). Free-8-isoprostanes in plasma were not altered with ribose-cysteine treatment (p = 0.33, Fig 2G). Analysis of a pooled sample of five aortic arches also showed a significant reduction in 8-isoprostanes in treated mice (1.26 ± 0.10 vs 3.77 ± 0.15 ng/mg protein in control, p< 0.005, Fig 2H).

Ribose-cysteine lowers LDL cholesterol levels

Total plasma and LDL cholesterol concentrations were significantly lower in the ribose-cysteine treated mice compared to control mice (6.15 ± 0.26 vs 7.33 ± 0.27 mmol/L, p< 0.005 and 5.57 ± 0.23 vs 6.68 ± 0.27 mmol/L respectively, p< 0.005, Fig 3A and 3B. The concentrations of plasma triglycerides and HDL cholesterol were not significantly different between the two groups (Fig 3C and 3D).

Fig 3

Ribose-cysteine decreases total plasma and LDL cholesterol in apoE-/-mice.

Total plasma cholesterol, HDL cholesterol and triglyceride levels were measured in ribose-cysteine treated and control apoE-/- mice (n = 15 per group) by enzymatic assay. LDL cholesterol levels were calculated by the Friedewald equation. (A) Total cholesterol, (B) LDL cholesterol, (C) HDL cholesterol, (D) Triglycerides. ** p < 0.005. Error bars indicate means ± SEM.

Ribose-cysteine increases SR-B1 but has no effect on LDLR or HMGCoA reductase protein levels

Western blot analysis of the LDLR and HMGCoA reductase protein showed no difference in protein amounts in the livers of treated versus control mice (S3 Fig). Western blot analysis of the SR-B1 protein showed an increased level in the livers of treated mice (S4 Fig).

Ribose-cysteine reduces atherosclerotic lesion area

Histological analysis of arteries showed the ribose-cysteine treated animals to have a significant reduction in the number and size of atherosclerotic lesions in the aortic sinus compared to controls (Fig 4A and 4B). The atherosclerotic lesion area in the brachiocephalic branch of the treated animals was also reduced compared to controls (Fig 4C and 4D). Quantitative analysis showed a significantly reduced lesion area (>50% reduction) in the treated mice compared to controls both in the aortic sinus (127.16 ± 30.64 vs 217.38 ± 27.74 103μm2, p< 0.05, Fig 4E) and brachiocephalic branch (5.74 ± 1.75 vs 41.6 ± 17.1 103μm2, p< 0.05, Fig 4F).

Fig 4

Ribose-cysteine reduces atherosclerotic lesion area in the apoE-/-mice.

Aortae from apoE-/- mice (20 weeks) were harvested and sectioned for histological staining and measurement of atherosclerotic lesion area. (A, B) Representative staining of the aortic sinus from control and treated mice, respectively. (C, D) Representative staining of the brachiocephalic branch from control and treated mice, respectively. Arrows indicate atherosclerotic lesion area. (E, F) Quantitation of total lesion area in the aortic sinus (n = 9) and brachiocephalic branch (n = 9). *p< 0.05. Error bars indicate means ± SEM.

Discussion

Decreased GSH and GPx activity is associated with cardiovascular disease in humans and has been documented in mouse models of atherosclerosis [14, 15]. Here, we show that the cysteine analogue, ribose-cysteine, can enhance GSH and GPx activity in the apoE-/- mouse model of atherosclerosis resulting in protection from disease development. Furthermore, ribose-cysteine showed both hepatoprotective and LDL-lowering effects.

Ribose-cysteine was developed based on its predecessor NAC, a prodrug for delivering L-cysteine, a limiting factor for GSH synthesis in the liver [31]. Elevating GSH protects the liver from damage in situations of acute oxidative stress such as paracetamol overdose [31, 32]. Although still mainly used as an antidote to paracetamol overdose, NAC is currently registered as in use for over 300 trials [33]. Ribose-cysteine is a registered therapeutic goods approved dietary supplement which gives a slower more controlled release of L-cysteine than NAC reducing the potential for toxicity [19]. However, studies on ribose-cysteine are limited and its affect mainly only studied in acute oxidative stress conditions in rodents where it has been shown to increase GSH levels in multiple tissues without toxicity [34, 35]. Only one study has investigated the longer term effect of ribose-cysteine showing that daily supplementation (4 mg/day) in the Lp(a) mouse model of hyperlipidaemia for 8 weeks promotes a significant increase in GSH and GPx in the liver and blood, without toxicity [20].

The current study looked at the effect of 8 weeks supplementation (4–5 mg/day) with ribose-cysteine in the apoE-/- mouse model of atherosclerosis over a time period (20 weeks of age) at which disease develops [21]. ApoE-/- mice of a similar age also display elevated levels of plasma ALT [36] with older mice developing hepatotoxicity and fatty livers [37]. Here we showed that ribose-cysteine is rapidly metabolised (either via hydrolysis in the gut or in circulation) with no accumulation of either L-cysteine or D-ribose in the plasma of treated animals. The released L-cysteine appeared to be readily taken up by the liver to promote GSH synthesis as indicated by the increased liver GSH levels in treated animals. The increased GSH levels may protect against the development of hepatotoxicity as indicated by a significant reduction in plasma ALT levels. This was likely driven by the increase in GPx activity lowering 8-isoprostanes and the potential for oxidative damage of hepatocytes. The increase in liver GSH in the apoE-/- mice, however, unlike the Lp(a) mice [20], did not translate to an increase in plasma GSH levels. The apoE-/- mice displays a more severe lipid phenotype than Lp(a) mice, promoting oxidative stress that likely drives a higher GSH utilisation in the liver leaving less GSH available for export into plasma. Alternatively, an increased requirement for GSH in other tissues under oxidative stress could drive an influx of GSH into other tissues.

ApoE-/- mice show a marked depletion in GSH in the aortic arch before the onset of atherosclerosis due to reduced GSH synthesis [15]. This is associated with a downregulation of GPx1 and increase in lipid peroxidation markers [15]. Mice deficient in GPx1 also have increased levels of aortic isoprostanes along with endothelial dysfunction and structural changes in the artery [38]. GPx1 is expressed in macrophages in the aorta and its expression in peripheral macrophages protects against oxidised LDL-induced foam cell formation [39]. The importance of Gpx1 activity is very apparent in apoE-/-/Gpx1-/-mice which display greatly accelerated atherosclerosis development [24], which is attenuated by treatment with the GPx mimetic, ebselen [40].

In the current study, we show that supplementation with ribose cysteine is associated with a significant reduction in atherosclerotic plaque area in both the aortic sinus and the brachiocephalic arch of apoE-/- mice. This atheroprotective effect is likely attributed to an attenuation of the GSH/GPx depletion previously established in the aortae of these mice as evident by a significant reduction in aortic 8-isoprostanes.

Our study is in keeping with previous studies showing that NAC inhibits atherosclerosis in apoE-/- mice [41, 42]. A more recent study in LDLR-/- mice has shown that NAC effectively inhibits in vivo oxidation of LDL [43]. Furthermore, the study showed that NAC was capable of significantly decreasing the level of oxLDL in hyperlipidaemic patients [43]. One effect we established in the ribose-cysteine treated apoE-/- mice, which was not reported for NAC, was that of a significant LDL-lowering effect. This effect had been noted previously in Lp(a) mice treated with ribose-cysteine [20] and seemed to be due to an upregulation in the LDLR. However, in the apoE-/- mice, there were no changes in the protein levels of either LDLR or HMGCoA reductase with ribose-cysteine treatment, suggesting no effect on LDL uptake or cholesterol synthesis via the SREPB2 pathway. These results indicate that an alternative mechanism for LDL-lowering with ribose-cysteine treatment might exist in the apo E-/- model. As a previous study had shown that overexpression of the scavenger receptor, SR-B1, significantly lowered LDL cholesterol levels in chow and fat-fed mice [44], we investigated the protein levels of SR-B1. We saw a significant increase in SR-B1 levels in the ribose-cysteine treated mice which could underpin the reduction in LDL cholesterol levels seen in our study. The LDL-lowering effect of ribose-cysteine may provide further atheroprotection secondary to the GSH-based antioxidant effect.

Conclusions

In summary, ribose-cysteine is utilised in the circulation to increases GSH levels and GPx activity and appears to provide protection against the development of atherosclerosis. It also displays cholesterol-lowering properties and hepatoprotective effects that could provide further health benefits. Clinical trials of this dietary supplement are needed to evaluate whether these results translate to humans.

Stability of ribose-cysteine (20 μM) in plasma or water up to 48 hours.

The raw response data was normalised to an internal standard (13C6 sorbitol) to account for instrumental variations and the normalised response were plotted over the incubation time. The stability experiments were performed at room temperature.

(DOCX)

Click here for additional data file.

Ribose-cysteine-related metabolites detected in plasma and compared between the two groups.

The data is presented as mean fold difference in peak areas ±standard deviation after median normalisation. Student t-test with Benjamini-hochberg correction was used for statistical analysis using R (v3.3.1).

(DOCX)

Click here for additional data file.

Ribose-cysteine has no effect on levels of the low-density lipoprotein receptor (LDLR) and the HMGCoA reductase protein in the liver.

The LDLR (A) and HMGCoA reductase (B) proteins were analysed by western blotting of liver homogenates (40μg) from treated and control mice. Representative blots for 13 control and 14 treated mice are shown.

(DOCX)

Click here for additional data file.

Ribose-cysteine increases SR-B1 protein expression in the liver.

The SR-B1 protein was analysed by western blotting of liver homogenates (40μg) from treated and control mice. Representative blots for 15 control and 15 treated mice are shown. Fold difference of relative SR-B1 protein, **p<0.01, Kolmogorov-Smirnov test was used for statistical analysis. Error bars indicate means ± SEM.

(DOCX)

Click here for additional data file.

Raw data of all main figures.

(XLSX)

Click here for additional data file.

Uncropped western blots.

(PPTX)

Click here for additional data file.

All images of atherosclerotic lesion area in the apoE-/- mice.

(PPTX)

Click here for additional data file.

17 Oct 2019

PONE-D-19-25760

Ribose-cysteine protects against the development of atherosclerosis in apoE-deficient mice

PLOS ONE

Dear Associate Professor McCormick,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. In particular more experiments are necessary concerning the mechansim of LDL reduction and the verification of the effect on atherosclerosis.

We would appreciate receiving your revised manuscript by Dec 01 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Bader

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

1. The Western blots in Figure S3 are closely cropped. Please provide the original uncropped and unadjusted blots in the figures or supporting information. Please see https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements

PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

2. Thank you for including your funding statement; "This study was supported by funding from Max International, LLC, Salt Lake City, UT, USA who provided the ribose-cysteine and by an Otago School of Medical Sciences Bequest Fund. ST was supported by an Otago Postgraduate Research Scholarship."

We note that you received funding from a commercial source: [Name of Company]

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Within this Competing Interests Statement, please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: http://journals.plos.org/plosone/s/competing-interests

3. Please specify the method of sacrifice in your methods section.

4.

In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: No

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting manuscript about a cysteine analogue producing benefic effects on atherosclerosis disease. This manuscript is a follow up of previous publication of these authors.

The experiments support the manuscript conclusions

The manuscript is clearly enough to be accessible to non-specialists

Histology is impressive; the figures show an important decrease of atherosclerosis plaque in treated mice

Reviewer #2: The manuscript by Kader et al investigated the effect of ribose-cysteine supplementation on GSH-based antioxidant activity and atherosclerosis development in the apoE-/- mouse. However, the experiments and manuscript are poorly conducted and written. The novelty is limited. They have reported that ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice. In the previous paper, they found ribose-cysteine increases LDLR gene and protein expression. In this manuscript, they thought ribose-cysteine does not affect LDLR. More experiments should be conducted to confirm and discuss the effects of ribose-cysteine on LDLR. If LDLR was not affected by ribose-cysteine, they should conduct more experiments to explain the reduced LDL cholesterol by ribose-cysteine. Furthermore, they did not provide enough evidence to support the conclusion that ribose-cysteine reduces atherosclerotic lesion area. The en face lesions of artery should be determined to confirm the effects of ribose-cysteine on atherosclerosis. In addition, more staining assays should be conducted such as oil red O staining.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

4 Jan 2020

We thank the editors(s) and reviewers for their constructive comments and suggestions. All changes are highlighted in Red in the revised manuscript.

Journal Requirements

1. The Western blots in Figure S3 are closely cropped. Please provide the original uncropped and unadjusted blots in the figures or supporting information. Please see https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements

We have followed the PLOS ONE requirements for blot results and have provided the original uncropped and unadjusted blots for the revised Figure S3 (and the new figure S4) according to these guidelines in a new additional supporting file (Additional File 3).

2. Thank you for including your funding statement; "This study was supported by funding from Max International, LLC, Salt Lake City, UT, USA who provided the ribose-cysteine and by an Otago School of Medical Sciences Bequest Fund. ST was supported by an Otago Postgraduate Research Scholarship."

We note that you received funding from a commercial source: [Name of Company]

Please provide an amended Competing Interests Statement that explicitly states this commercial funder, along with any other relevant declarations relating to employment, consultancy, patents, products in development, marketed products, etc.

Please include your amended Competing Interests Statement within your cover letter. We will change the online submission form on your behalf.

Here is our competing interest statement prepared in line with PLOS One's policy on competing interests:

"The funder Max International provided support in the form of a salary for one of the author's conducting the research [TK] and some of the research materials including ribose-cysteine for which they own the patent and commercial license. The funder did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section. The commercial affiliation with Max International does not alter our adherence to PLOS ONE policies on sharing data and materials. The authors do not have any other competing interests in form of consultancy, patents, products in development, or marketed products, etc."

3. Please specify the method of sacrifice in your methods section.

The method of sacrifice (CO2 inhalation) has been added to the methods section.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

We have added supporting information (original blots for revised Figures S3 and S4, images to support the lesion analysis plus raw lesion analysis data as well as all of the raw data points for all main figures as Additional Files 2 to 4) to fulfil the minimal data set requirement.

Here is our Data Availability Statement prepared in line with PLOS One's policy on Data Availability:

" The underlying results required to replicate the study can be found in the paper and additional files containing supplementary and original data."

Review Comments to Author:

Reviewer #2: The manuscript by Kader et al investigated the effect of ribose-cysteine supplementation on GSH-based antioxidant activity and atherosclerosis development in the apoE-/- mouse. However, the experiments and manuscript are poorly conducted and written. The novelty is limited. They have reported that ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice. In the previous paper, they found ribose-cysteine increases LDLR gene and protein expression. In this manuscript, they thought ribose-cysteine does not affect LDLR. More experiments should be conducted to confirm and discuss the effects of ribose-cysteine on LDLR. If LDLR was not affected by ribose-cysteine, they should conduct more experiments to explain the reduced LDL cholesterol by ribose-cysteine. Furthermore, they did not provide enough evidence to support the conclusion that ribose-cysteine reduces atherosclerotic lesion area. The en face lesions of artery should be determined to confirm the effects of ribose-cysteine on atherosclerosis. In addition, more staining assays should be conducted such as oil red O staining.

Regarding more experiments to confirm and discuss the mechanism of LDL reduction, we have performed more experiments to investigate the levels of other appropriate targets. We investigated the protein levels of HMGCoA reductase, a key regulator of cholesterol synthesis (see revised Figure S3) and the protein levels were unchanged. Combined with the results for the LDLR, this confirms that the SREBP2a pathway, a key regulator of both proteins was not affected by ribose-cysteine. We also investigated the protein levels of the scavenger receptor, SR-B1 which is implicated in both LDL and OxLDL removal. We saw an increase in the protein level of SR-B1 (see new Figure S4) which may underlie the reduction in LDL cholesterol levels.

We have added the revised Figure S3 and new Figure S4 and have added further discussion on the possible mechanism of LDL-lowering (see page 18 of the revised manuscript including the addition of a relevant reference (reference 44).

Regarding the comment that not enough evidence was provided to support the conclusion that ribose-cysteine reduces atherosclerosis lesion area, we point out that this comment is in complete contrast to reviewer 1 who thought the histology had been done well and was impressed with the lesion analysis. Nevertheless, we have provided the images from individual animals for both the aortic sinus and brachiocephalic branch and the raw data for lesion area analysis for both regions in additional data files (Additional Files 2 and 4) to satisfy this critique. We have also detailed in the methods (page 9) how the anatomical location of the sections that were quantified from each mouse were chosen to ensure assessment of a similar anatomical location for an accurate comparison. The reviewer also suggested that we should have used the en face method and also stained our current sections with oil red O. En-face staining requires fresh tissue but the histological assessment we choose to perform requires formalin fixed tissue so unfortunately both assessments cannot be performed. Furthermore, as the lipid is removed by the embedding solvents used in processing the formalin-fixed tissue for sectioning, we cannot retrospectively stain our sections with oil red O. The assessment we did perform using histological stains for elastin and collagen is a well-accepted and published form of atherosclerosis assessment (see papers from Erling Falk's laboratory which has published many papers on atherosclerosis assessment in mice i.e. Shim et al Arterioscler Thromb Vasc Biol (2011) 31:1814-20 and earlier papers by Falks group in the same journal). Histological assessment allows for a more precise comparison between individual animals (and therefore groups of animals) since the anatomical location of the section used for quantification is pinpointed using anatomical landmarks and kept the same. Furthermore, more information can be gained about the composition and extent of the lesions i.e. foam cells and cholesterol crystals can be seen which can't be visualised with en face staining which only shows fat content. En face staining is not as accurate for determining the extent of atherosclerosis in animals in the earlier stages of atherosclerosis as were our animals at 20 weeks. Most atherosclerosis studies performed on apo E -/- mice are performed in animals significantly older than 20 weeks that have developed atherosclerotic lesions throughout the length of aorta. Here we performed a more targeted analysis to the two regions known to initially develop atherosclerosis. We hope that the additional data and additional detail we have added to the methods, along with the justification of why we performed a histological assessment rather than use the en-face method, will satisfy this point.

Submitted filename: Kader et al PONE-D-19-25760_Response to Reviewers.docx

Click here for additional data file.

15 Jan 2020

Ribose-cysteine protects against the development of atherosclerosis in apoE-deficient mice

PONE-D-19-25760R1

Dear Dr. McCormick,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Michael Bader

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

6 Feb 2020

PONE-D-19-25760R1

Ribose-cysteine protects against the development of atherosclerosis in apoE-deficient mice

Dear Dr. McCormick:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Michael Bader

Academic Editor

PLOS ONE